Brief: Plus Therapeutics Showcases New Interim Respect-Gbm Phase 2 Trial Data At The 2024 Congress Of Neurological Surgeons Annual Meeting
18/09/2024 13:37
Sept 18 (Reuters) - Plus Therapeutics Inc PSTV.O :
* PLUS THERAPEUTICS SHOWCASES NEW INTERIM RESPECT-GBM PHASE
2
TRIAL DATA AT THE 2024 CONGRESS OF NEUROLOGICAL SURGEONS ANNUAL
MEETING
Source text for Eikon: ID:nGNX3CsCGS
Further company coverage: PSTV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer